Showing results (11-20 of 133) with videos related to

Sort By:
Pageof 14
Diabetes Care|September 28, 2005
Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trialGregory G Schwartz, Anders G Olsson, Michael Szarek, et al.
European Journal of Preventive Cardiology|May 16, 2017
Early, intensive statin treatment reduces 'hard' cardiovascular outcomes after acute coronary syndromeGregory G Schwartz, Rana Fayyad, Michael Szarek, et al.
The American Journal of Cardiology|February 24, 2007
Effects of high-dose atorvastatin in patients > or =65 years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering [MIRACL] study)Anders G Olsson, Gregory G Schwartz, Michael Szarek, et al.
American Heart Journal Plus : Cardiology Research and Practice|February 18, 2026
Novel cholesterol lowering drugs: Can phase 2/3 clinical trial safety assessments predict cardiovascular event outcome trial efficacy?Charles Shear, Michael H Davidson, Marc Ditmarsch, et al.
International Journal of Cancer|February 2, 2006
Cytoplasmic melanoma-associated antigen (CYT-MAA) serum level in patients with melanoma: a potential marker of response to immunotherapy?Sandra R Reynolds, Irene J Vergilis, Michael Szarek, et al.
Brain and Behavior|November 10, 2012
Maximum carotid artery wall thickness and risk factors in a young primary prevention populationA S Callahan, Michael Szarek, John W Patton, et al.
Circulation|July 21, 2004
Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) StudyScott Kinlay, Gregory G Schwartz, Anders G Olsson, et al.
Circulation|September 9, 2004
High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trialSotirios Tsimikas, Joseph L Witztum, Elizabeth R Miller, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 10, 2007
Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL studyScott Kinlay, Gregory G Schwartz, Anders G Olsson, et al.
Prehospital Emergency Care|January 28, 2014
Factors related to the sensitivity of emergency medical service impression of strokeToby I Gropen, Reshma Gokaldas, Rebecca Poleshuck, et al.
Pageof 14